Andrew Tobin studied Biochemistry at Queen Mary College, the University of London obtaining first-class honors before studying for a D.Phil at the University of Oxford. Following a post-doctoral period at Bristol Myers Squibb in Princeton USA, Andrew returned to the UK to establish his own laboratory at the University of Leicester. Funded through three consecutive Wellcome Trust Senior Research Fellowships Andrew established a reputation in the field of receptor signaling.
Now at the University of Glasgow, his primary research interests are focused on the rational design of novel drugs to treat the three global health challenges of dementia, asthma, and malaria. In this Andrew runs a research laboratory of around 15 staff supported by basic research grants investigating aspects of disease biology and the action of drugs in the context of disease. The vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics Ltd, a biotechnology company co-founded by Andrew with series A funding from the European Union.
Andrew is also the Director of the Advanced Research Centre (ARC) a collaborative initiative at the University of Glasgow underpinned by a £118M new build that will house over 550 researchers designed to drive interdisciplinary research.
-------------------------------------------
Become a #DrGPCR Ecosystem Member
-------------------------------------------
Imagine a world in which the vast majority of us are healthy.
The #DrGPCR Ecosystem is all about dynamic interactions between us who are working towards exploiting the druggability of #GPCR's. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.
To build our #GPCR Ecosystem, we created various enabling outlets.
-------------------------------------------
Are you a #GPCR professional?
